Preclinical characterization of the novel hepatitis C virus NS3 protease inhibitor GS-9451.

@article{Yang2014PreclinicalCO,
  title={Preclinical characterization of the novel hepatitis C virus NS3 protease inhibitor GS-9451.},
  author={Huiling Yang and Margaret Robinson and Amoreena C. Corsa and Betty Peng and Guofeng Cheng and Yang Tian and Yujin Wang and Rowchanak Pakdaman and Marian Shen and Xiaoping Qi and Hongmei Mo and Chin Yen Alfred Tay and Steve H. Krawczyk and X Christopher Sheng and Choung U. Kim and Chris Yang and William E. Delaney},
  journal={Antimicrobial agents and chemotherapy},
  year={2014},
  volume={58 2},
  pages={647-53}
}
GS-9451 is a selective hepatitis C virus (HCV) NS3 protease inhibitor in development for the treatment of genotype 1 (GT1) HCV infection. Key preclinical properties of GS-9451, including in vitro antiviral activity, selectivity, cross-resistance, and combination activity, as well as pharmacokinetic properties, were determined. In multiple GT1a and GT1b… CONTINUE READING